Wall Street analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB) to report earnings of ($0.86) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Selecta Biosciences’ earnings. Selecta Biosciences reported earnings of ($2.75) per share in the same quarter last year, which indicates a positive year over year growth rate of 68.7%. The business is expected to report its next quarterly earnings results on Tuesday, August 8th.

On average, analysts expect that Selecta Biosciences will report full year earnings of ($2.63) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($3.14) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Selecta Biosciences.

Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.40. The business had revenue of $0.14 million for the quarter. Selecta Biosciences had a negative net margin of 715.40% and a negative return on equity of 76.21%.

A number of equities analysts have recently weighed in on SELB shares. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 8th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Selecta Biosciences in a research note on Tuesday, March 28th. Finally, Canaccord Genuity set a $25.00 price objective on shares of Selecta Biosciences and gave the company a “buy” rating in a research note on Saturday, May 13th.

ILLEGAL ACTIVITY WARNING: “Selecta Biosciences, Inc. (SELB) Expected to Post Earnings of -$0.86 Per Share” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/12/selecta-biosciences-inc-selb-expected-to-post-earnings-of-0-86-per-share.html.

In related news, COO Lloyd P. Johnston sold 13,205 shares of the stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $13.95, for a total value of $184,209.75. Following the sale, the chief operating officer now directly owns 14,811 shares of the company’s stock, valued at approximately $206,613.45. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Timothy A. Springer acquired 16,104 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $225,456.00. Following the completion of the purchase, the director now owns 11,244 shares in the company, valued at approximately $157,416. The disclosure for this purchase can be found here.

A number of large investors have recently modified their holdings of SELB. Deerfield Management Co. acquired a new stake in shares of Selecta Biosciences during the fourth quarter worth approximately $14,632,000. Perceptive Advisors LLC acquired a new stake in shares of Selecta Biosciences during the fourth quarter worth approximately $2,433,000. State Street Corp acquired a new stake in shares of Selecta Biosciences during the fourth quarter worth approximately $1,195,000. UBS Group AG boosted its stake in shares of Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock worth $1,022,000 after buying an additional 65,938 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of Selecta Biosciences during the first quarter worth approximately $444,000. 46.50% of the stock is currently owned by hedge funds and other institutional investors.

Selecta Biosciences (NASDAQ SELB) traded up 5.50% during trading on Monday, reaching $15.92. 262,338 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $13.55 and its 200-day moving average price is $15.35. Selecta Biosciences has a one year low of $10.26 and a one year high of $28.00.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.